Biopsy Confirmed Skin Drug Eruption in Setting of Ticagrelor Use
When there is concern that a rash may be a drug eruption reaction, there are many well-known culprits such as antibiotics and phenytoin. When an uncommon or previously unknown offending medication is being considered to have caused a drug eruption, diagnostic skin biopsy can help confirm the diagnosis. Our patient is a 54-year-old female with past medical history of prediabetes and obesity. She had ST segment-elevation myocardial infarction that was treated appropriately with timely percutaneous coronary intervention, which included angioplasty and drug-eluting stent placement. She was maintained on treatment regimen, and over the next 3 months, she developed a worsening maculopapular rash across her torso and upper extremities. Her biopsy showed superficial and mid-dermal perivascular lymphohistiocytic inflammation with focal spongiosis and scattered eosinophils, a common pathologic finding seen in drug eruptions. Although the patient was not taking any well-known offending agents, her ticagrelor was discontinued and she was transitioned to clopidogrel. Shortly after the transition, the patient's drug rash resolved without recurrence. Drug eruptions are a common etiology for rashes leading to presentation in primary care clinics. Our patient illustrates an exceedingly rare case of ticagrelor-induced drug reaction, as a review of the literature shows only 2 previously published case reports.
Authors
- Aaron A.H. Smith (ORCID: https://orcid.org/0000-0003-0559-3768)
- Charles Cunningham
- DRE STEINWEHR
- Derek S. Anderson
- JENA GALES
- Anya R de Leeuw (ORCID: https://orcid.org/0009-0009-5576-8248)
Institutions
- Sanford Health (US)
- University of Arizona (US)
- University of Phoenix (US)
- University of North Dakota (US)
Publication Details
- Journal
- Journal of Investigative Medicine High Impact Case Reports
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1177/23247096251350547
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00